Clinical Outcomes of Patients Receiving Stereotactic Body Radiotherapy Dose De-escalation for Hepatocellular Carcinoma at the Hepatic Hilum.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-03-01 DOI:10.21873/anticanres.17503

Takeshi Fujisawa, Hidehiro Hojo, Masaki Nakamura, Kenji Makita, Hidenari Hirata, Hidekazu Oyoshi, Kento Tomizawa, Yuzheng Zhou, Keiko Fukushi, Masafumi Ikeda, Sadamoto Zenda

{"title":"Clinical Outcomes of Patients Receiving Stereotactic Body Radiotherapy Dose De-escalation for Hepatocellular Carcinoma at the Hepatic Hilum.","authors":"Takeshi Fujisawa, Hidehiro Hojo, Masaki Nakamura, Kenji Makita, Hidenari Hirata, Hidekazu Oyoshi, Kento Tomizawa, Yuzheng Zhou, Keiko Fukushi, Masafumi Ikeda, Sadamoto Zenda","doi":"10.21873/anticanres.17503","DOIUrl":null,"url":null,"abstract":"Background/aim: Stereotactic body radiation therapy (SBRT) for centrally located hepatocellular carcinomas (HCCs) can cause severe central biliary toxicity. However, dose de-escalation SBRT has the potential to reduce biliary toxicity with excellent tumor control. Therefore, we aimed to retrospectively evaluate the efficacy and toxicity of de-escalated SBRT in patients with hepatic hilum HCC.Patients and methods: Patients diagnosed with peripherally located HCC received SBRT (40 Gy in five fractions), and those with centrally located HCC received de-escalated SBRT (35 Gy in five fractions) between January 2016 and August 2023 in National Cancer Center Hospital East.Results: Of the total 42 consecutive patients evaluated, 16 (38%) were diagnosed with centrally located HCC. The median observation time was 25 months (interquartile range=10-43). The 2-year cumulative incidences of local recurrence were 17.3% and 8.1% in patients with centrally and peripherally located HCC, respectively. No statistically significant differences were observed in the cumulative incidence of local recurrence, OS, or PFS between patients with centrally and peripherally located HCC. Univariate analysis of OS showed that a smaller clinical target volume of <20 ml was significantly associated with a better OS compared to a larger volume (p=0.017). No patient experienced grade 3 or higher treatment-related adverse events.Conclusion: Dose de-escalation SBRT for centrally located HCC showed good local control with no grade 3 or more RT related toxicities, suggesting it may be a safe alternative.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1159-1169"},"PeriodicalIF":1.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17503","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Stereotactic body radiation therapy (SBRT) for centrally located hepatocellular carcinomas (HCCs) can cause severe central biliary toxicity. However, dose de-escalation SBRT has the potential to reduce biliary toxicity with excellent tumor control. Therefore, we aimed to retrospectively evaluate the efficacy and toxicity of de-escalated SBRT in patients with hepatic hilum HCC.

Patients and methods: Patients diagnosed with peripherally located HCC received SBRT (40 Gy in five fractions), and those with centrally located HCC received de-escalated SBRT (35 Gy in five fractions) between January 2016 and August 2023 in National Cancer Center Hospital East.

Results: Of the total 42 consecutive patients evaluated, 16 (38%) were diagnosed with centrally located HCC. The median observation time was 25 months (interquartile range=10-43). The 2-year cumulative incidences of local recurrence were 17.3% and 8.1% in patients with centrally and peripherally located HCC, respectively. No statistically significant differences were observed in the cumulative incidence of local recurrence, OS, or PFS between patients with centrally and peripherally located HCC. Univariate analysis of OS showed that a smaller clinical target volume of <20 ml was significantly associated with a better OS compared to a larger volume (p=0.017). No patient experienced grade 3 or higher treatment-related adverse events.

Conclusion: Dose de-escalation SBRT for centrally located HCC showed good local control with no grade 3 or more RT related toxicities, suggesting it may be a safe alternative.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.